Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (IRD)
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Compensation Committee of its Board of Directors approved an equity award under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to one non-executive employee who was not previously an employee or director of the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan. The equity award was granted in the form of options to purchase an aggregate of 50,000 shares of the Company’s common stock. The option award has an exercise price equal to the fair market value of an underlying
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best DiseaseGlobeNewswire
- Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.MarketBeat
IRD
Sec Filings
- 12/11/25 - Form SCHEDULE
- 12/11/25 - Form 4
- 11/12/25 - Form 10-Q
- IRD's page on the SEC website